{"id":972124,"date":"2026-06-15T11:04:58","date_gmt":"2026-06-15T15:04:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/"},"modified":"2026-06-15T11:04:58","modified_gmt":"2026-06-15T15:04:58","slug":"intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/","title":{"rendered":"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets.<\/i>\n      <\/p>\n<p align=\"justify\">\n        <b>NEW YORK and HERZLIYA, Israel, June  15, 2026  (GLOBE NEWSWIRE) &#8212; InterCure Ltd.\u00a0<\/b>(Nasdaq: INCR) (TASE: INCR) (\u201c<b>InterCure<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today announced the successful completion of the first tranche of its acquisition of Botanico Ltd. (\u201cBotanico\u201d), also known as ISHI, an Israeli cannabis technology and brand company.\u00a0<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Following the recent U.S. federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III, InterCure has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">The Botanico transaction further strengthens InterCure\u2019s portfolio through exclusive rights to a broad collection of award-winning American cannabis genetics, proprietary strains, premium brands and advanced production technologies.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Through the Botanico transaction, InterCure gains access to ISHI\u2019s advanced AI-driven technologies, automated production systems and exclusive strategic brand alliances with leading U.S. cannabis operators, including The Flowery.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">As part of the initial closing of the transaction, InterCure will issue 2,471,061 ordinary shares Upon satisfaction of the conditions specified in the share purchase agreement, InterCure will issue an additional 2,470,073 ordinary shares..<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Earlier this year, InterCure reported its first meaningful revenues from the rapidly growing German medical cannabis market, supporting its strategy of building a leading international pharmaceutical cannabis platform.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">To support growing demand, InterCure has appointed a German management and sales team and anticipates multiple product launches in the second half of the year.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">The Company\u2019s evaluation of opportunities in the United States is focused exclusively on regulated medical cannabis markets.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Alexander Rabinovitch<\/b>, Chief Executive Officer and Chairman of InterCure, commented, \u201cThe Botanico acquisition, German market momentum and evolving U.S. regulatory landscape support the Company\u2019s vision of building a leading international medical cannabis company serving patients across multiple regulated markets.\u201d\u00a0<\/p>\n<p align=\"justify\">\n        <b>About InterCure (dba Canndoc)<\/b>\n      <\/p>\n<p align=\"justify\">InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel\u2019s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated \u201cseed-to-sale\u201d model to lead the fastest growing cannabis global market outside of North America.<\/p>\n<p align=\"justify\">For more information, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NTM8YcdOVq9mFhoZl9oJ1vFp2n2vObGPuQEGQ74OwhvwkHvHrDX7aIL2nVJULKuq8ykxCKsi9kpu7y_vPEem9M_-Zr4OBcWt6M611C7CF2M=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.intercure.co<\/a><\/p>\n<p align=\"justify\">\u00a0<b>Forward-Looking Statements<\/b><\/p>\n<p align=\"justify\">This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding the expected benefits of the Botanico transaction, the Company\u2019s integration plans, the issuance of additional consideration and other expected events pursuant to the terms of the share purchase agreement, growth opportunities in Germany, the Company\u2019s strategic review of regulated U.S. medical cannabis opportunities, and the Company\u2019s future strategy, product launches, operations and performance, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as \u201cbelieves,\u201d \u201chopes,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cshould,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cpositioned,\u201d \u201cstrategy\u201d and similar expressions and are based on assumptions and assessments made in light of management\u2019s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure\u2019s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the ability to realize the anticipated benefits of the Botanico transaction; the successful integration of Botanico; the satisfaction of conditions under the share purchase agreement; developments in regulated U.S. medical cannabis markets; and the Company\u2019s ability to execute its strategy in Germany and other international markets. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure\u2019s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscape and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading \u201cRisk Factors\u201d included in the Company\u2019s most recent Annual Report on Form 20-F, and in other filings that the Company has made and may make with the Securities and Exchange Commission in the future.<\/p>\n<p align=\"justify\">\n        <b>Company Contact:<\/b>\n      <\/p>\n<p align=\"justify\">InterCure Ltd.<br \/>Amos Cohen, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0HBiEx37uhcXiHLBGRRwC0USOCd2_BfpPGH16zixHEpT4E5SeqtMtiKP2PGGHaTwXADydfzYjF-93UMNmUKOJovRH12b68DqTWLEgFkmVeY=\" rel=\"nofollow\" target=\"_blank\">amos@intercure.co<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODEyYzY5YjctYzdlZC00YjU5LWJkZDItYzQ4MWM2YjVmMzQxLTUwMDE1ODc0OS0yMDI2LTA2LTE1LWVu\/tiny\/InterCure-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets. NEW YORK and HERZLIYA, Israel, June 15, 2026 (GLOBE NEWSWIRE) &#8212; InterCure Ltd.\u00a0(Nasdaq: INCR) (TASE: INCR) (\u201cInterCure\u201d or the \u201cCompany\u201d) today announced the successful completion of the first tranche of its acquisition of Botanico Ltd. (\u201cBotanico\u201d), also known as ISHI, an Israeli cannabis technology and brand company.\u00a0 Following the recent U.S. federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III, InterCure has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets. The Botanico transaction further &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972124","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets. NEW YORK and HERZLIYA, Israel, June 15, 2026 (GLOBE NEWSWIRE) &#8212; InterCure Ltd.\u00a0(Nasdaq: INCR) (TASE: INCR) (\u201cInterCure\u201d or the \u201cCompany\u201d) today announced the successful completion of the first tranche of its acquisition of Botanico Ltd. (\u201cBotanico\u201d), also known as ISHI, an Israeli cannabis technology and brand company.\u00a0 Following the recent U.S. federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III, InterCure has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets. The Botanico transaction further &hellip; Continue reading &quot;InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T15:04:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition\",\"datePublished\":\"2026-06-15T15:04:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/\"},\"wordCount\":872,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/\",\"name\":\"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==\",\"datePublished\":\"2026-06-15T15:04:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/","og_locale":"en_US","og_type":"article","og_title":"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition - Market Newsdesk","og_description":"First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets. NEW YORK and HERZLIYA, Israel, June 15, 2026 (GLOBE NEWSWIRE) &#8212; InterCure Ltd.\u00a0(Nasdaq: INCR) (TASE: INCR) (\u201cInterCure\u201d or the \u201cCompany\u201d) today announced the successful completion of the first tranche of its acquisition of Botanico Ltd. (\u201cBotanico\u201d), also known as ISHI, an Israeli cannabis technology and brand company.\u00a0 Following the recent U.S. federal rescheduling of certain state-licensed medical cannabis from Schedule I to Schedule III, InterCure has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets. The Botanico transaction further &hellip; Continue reading \"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-15T15:04:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition","datePublished":"2026-06-15T15:04:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/"},"wordCount":872,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/","name":"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==","datePublished":"2026-06-15T15:04:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0Njk4OCM3NjYxNzMyIzUwMDE1ODc0OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-initiates-strategic-review-of-u-s-medical-cannabis-opportunities-following-historic-federal-rescheduling-and-completes-the-initial-closing-of-botanico-acquisition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972124"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972124\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}